Orphazyme (Denmark) Performance
| ORPHA Stock | DKK 950.00 39.80 4.02% |
On a scale of 0 to 100, Orphazyme holds a performance score of 5. The company holds a Beta of -0.56, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Orphazyme are expected to decrease at a much lower rate. During the bear market, Orphazyme is likely to outperform the market. Please check Orphazyme's expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Orphazyme's historical price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Orphazyme AS are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating fundamental indicators, Orphazyme exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 726.9 M | |
| Total Cashflows From Investing Activities | 46 K |
Orphazyme |
Orphazyme Relative Risk vs. Return Landscape
If you would invest 82,420 in Orphazyme AS on September 12, 2024 and sell it today you would earn a total of 12,580 from holding Orphazyme AS or generate 15.26% return on investment over 90 days. Orphazyme AS is generating 0.3277% of daily returns and assumes 4.6566% volatility on return distribution over the 90 days horizon. Simply put, 41% of stocks are less volatile than Orphazyme, and 94% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Orphazyme Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orphazyme's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Orphazyme AS, and traders can use it to determine the average amount a Orphazyme's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0704
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ORPHA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.66 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.33 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Orphazyme is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orphazyme by adding it to a well-diversified portfolio.
Orphazyme Fundamentals Growth
Orphazyme Stock prices reflect investors' perceptions of the future prospects and financial health of Orphazyme, and Orphazyme fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orphazyme Stock performance.
| Return On Equity | -4.87 | |||
| Return On Asset | -1.33 | |||
| Profit Margin | (2.76) % | |||
| Operating Margin | (15.38) % | |||
| Current Valuation | (12.81 M) | |||
| Shares Outstanding | 35.31 M | |||
| Price To Book | 0.47 X | |||
| Price To Sales | 1.05 X | |||
| Revenue | 36.19 M | |||
| EBITDA | (603.91 M) | |||
| Cash And Equivalents | 726.93 M | |||
| Cash Per Share | 20.80 X | |||
| Total Debt | 2.48 M | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 2.21 X | |||
| Cash Flow From Operations | (602.57 M) | |||
| Earnings Per Share | (17.94) X | |||
| Total Asset | 173.23 M | |||
About Orphazyme Performance
By analyzing Orphazyme's fundamental ratios, stakeholders can gain valuable insights into Orphazyme's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Orphazyme has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Orphazyme has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.Things to note about Orphazyme AS performance evaluation
Checking the ongoing alerts about Orphazyme for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Orphazyme AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orphazyme AS had very high historical volatility over the last 90 days | |
| The company reported the revenue of 36.19 M. Net Loss for the year was (626.54 M) with profit before overhead, payroll, taxes, and interest of 36.19 M. | |
| Orphazyme AS has accumulated about 726.93 M in cash with (602.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 20.8. |
- Analyzing Orphazyme's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orphazyme's stock is overvalued or undervalued compared to its peers.
- Examining Orphazyme's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orphazyme's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orphazyme's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orphazyme's stock. These opinions can provide insight into Orphazyme's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Orphazyme Stock analysis
When running Orphazyme's price analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's value examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |